Even less in the Seven Bucks wheelhouse (and devoid of a Johnson performance) is an upcoming documentary feature about ...

Della Rocca has taken on several CIO roles for J&J since 2019, when he became CIO for the company’s Janssen Pharmaceuticals ...

Biolojic Design, a biotechnology company that uses computational biology and artificial intelligence (AI) to transform antibodies into programmable, intelligent medicines, today announced that it is ...

Johnson & Johnson shows strong progress in oncology with Darzalex sales and regulatory filings, leading to a 'Buy' rating ...

"Johnson & Johnson MedTech announces partnership for soft tissue solutions" was originally created and published by Medical ...

Johnson & Johnson faces uncertainty with speculation about RFK Jr. at HHS. Learn why JNJ stock remains a buy despite political risks and soft trends.

Johnson & Johnson (JNJ) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Johnson & Johnson has a high three-year median payout ratio of 71% (or a retention ratio of 29%), meaning that the company is ...

Johnson & Johnson MedTech announced today that the FDA granted its Ottava surgical robot investigational device exemption ...

Protagonist Therapeutics (PTGX) announced positive topline results from its collaboration with Johnson & Johnson (JNJ), in ICONIC-LEAD1 and ...

However, HRSA resisted the plan, threatening to terminate Johnson & Johnson’s PPA and impose significant penalties. This ...

NEWARK, CA / ACCESSWIRE / November 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that the company will host a conference call and webcast to announce its ...